Revenues beat guidance at Oxford Nanopore, shares spark
Shares in Oxford Nanopore Technologies surged in early trading on Monday, after the FTSE 250 firm said full-year sales had beaten guidance.
Updating on year-end trading, the business - a specialist in nanopore-based molecular sensing technology - said revenues were set to come in between £223m and £224m.
That represents a 22% increase on 2024, or a 24% jump on a constant currency basis.
Oxford Nanopore had previously steered for an increase of between 20% and 23% on a constant currency basis.
It also flagged "continued progress" during the year on its path to profitability.
As at 0830 the stock had jumped 8% at 151.6p.
Driving the "strong" 2025 performance was a 60% surge in clinical revenues. All segments saw revenue growth, however, including biopharma - up 30% - and applied industrial, which reported a 27% spike in sales.
The business also confirmed it had ended the year with around £302m in cash, cash equivalents and other liquid investments, ahead of expectations, following improved working capital.
Oxford Nanopore said the higher-than-expected cash provided "continued balance sheet strength to support execution of the group strategy".
Oxford Nanopore, which was founded in 2005 as a spin out from the Oxford University, is due to publish results for the year to 31 December on 2 March.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
